Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05322954 · ClinicalTrials.gov registry record · Phase 1

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

A Phase 1 study of Substance Use Disorders and Substance-Related Disorders, sponsored by University of Wisconsin, Madison.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT05322954 is a Phase 1 study of Substance Use Disorders and Substance-Related Disorders that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05322954, a Phase 1 study of Substance Use Disorders and Substance-Related Disorders, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Interventions

  • DRUG Psilocybin

Study Locations (1)

Wisconsin

  • University of Wisconsin - Madison

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2023-03-03
Est. Completion 2026-05
Phase Phase 1

Sponsor

University of Wisconsin, Madison

1,039 total trials

What the Registry Record Tells You About NCT05322954

The ClinicalTrials.gov registry entry for NCT05322954 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.

NCT05322954 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05322954 about?

NCT05322954 is a clinical study titled "Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder". The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be activel...

What is the current status of trial NCT05322954?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-03-03. Estimated completion is 2026-05.

What conditions does trial NCT05322954 study?

This clinical trial studies the following conditions: Substance Use Disorders, Substance-Related Disorders, Methamphetamine Use Disorder, Stimulant Use Disorder, Chemically-Induced Disorders.

What interventions are being tested in trial NCT05322954?

The interventions under investigation include: Psilocybin (DRUG).

Who is sponsoring clinical trial NCT05322954?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05322954 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.